Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing

Nature Communications

Volumn 6, Issue , 2015, Pages

  Arulanandam, Rozanne ^a   Batenchuk, Cory ^a   Varette, Oliver ^a   Zakaria, Chadi ^b   Garcia, Vanessa ^a   Forbes, Nicole E ^a   Davis, Colin ^a   Krishnan, Ramya ^a   Karmacharya, Raunak ^a   Cox, Julie ^a   Sinha, Anisha ^a   Babawy, Andrew ^a   Waite, Katherine ^a   Weinstein, Erica ^a   Falls, Theresa ^a   Chen, Andrew ^a   Hamill, Jeff ^a   De Silva, Naomi ^a   Conrad, David P ^a   Atkins, Harold ^a   Garson, Kenneth ^a   Ilkow, Carolina ^a   Kærn, Mads ^c   Vanderhyden, Barbara ^a   Sonenberg, Nahum ^b   Alain, Tommy ^d   Le Boeuf, Fabrice ^a   Bell, John C ^a   Diallo, Jean Simon ^a   more..

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLCHICINE; INTERFERON; MESSENGER RNA; MICROTUBULE DESTABILIZING AGENT; NAVELBINE; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; ALBENDAZOLE; BENZIMIDAZOLE DERIVATIVE; CYTOKINE; NOCODAZOLE; PARBENDAZOLE; TUBULIN MODULATOR; VINBLASTINE;

ANTIMICROBIAL ACTIVITY; CANCER; DISEASE TREATMENT; DRUG; GENE EXPRESSION; INHIBITION; PROTEIN; RODENT; VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BYSTANDER EFFECT; CANCER MODEL; CELL DEATH; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INNATE IMMUNITY; MICROTUBULE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN SECRETION; RNA TRANSLATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; GENETICS; HT 29 CELL LINE; IMMUNOLOGY; METABOLISM; PROTEIN SYNTHESIS; RHABDOVIRIDAE; RHABDOVIRUS INFECTION; TUMOR CELL LINE; VERO CELL LINE;

MURINAE;

ALBENDAZOLE; ANIMALS; BENZIMIDAZOLES; BYSTANDER EFFECT; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COLCHICINE; CYTOKINES; HT29 CELLS; HUMANS; INTERFERON TYPE I; MICE; MICROTUBULES; NOCODAZOLE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROTEIN BIOSYNTHESIS; RHABDOVIRIDAE; RHABDOVIRIDAE INFECTIONS; RNA, MESSENGER; TUBULIN MODULATORS; VERO CELLS; VINBLASTINE;

EID: 84926366798     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7410     Document Type: Article

References (47)

1. Ilkow, C., Swift, S. L., Bell, J. C. & Diallo, J. S. From scourge to cure: tumourselective viral pathogenesis as a new strategy against cancer. PLoS Pathog. 10, e1003836 (2014).
2. Russell, S. J., Peng, K. W. & Bell, J. C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658-670 (2012).
3. Breitbach, C. J. et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477, 99-102 (2011).
4. Heo, J. et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19, 329-336 (2013).
5. Ottolino-Perry, K., Diallo, J. S., Lichty, B. D., Bell, J. C. & Andrea McCart, J. Intelligent design: combination therapy with oncolytic viruses. Mol. Ther. 18, 251-263 (2009).
6. Stojdl, D. F. et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6, 821-825 (2000).
7. Stojdl, D. F. et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4, 263-275 (2003).
8. Obuchi, M., Fernandez, M. & Barber, G. N. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 77, 8843-8856 (2003).
9. Faria, P. A. et al. VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol. Cell 17, 93-102 (2005).
10. Brun, J. et al. Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum. Int. J. Cancer. 132, 726-731 (2013).
11. Le Boeuf, F. et al. Model-based rational design of an oncolytic virus with improved therapeutic potential. Nat. Commun. 4, 1974 (2013).
12. Chang, H. M. et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc. Natl Acad. Sci. USA 101, 9578-9583 (2004).
13. Nguyen, T. L. et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl Acad. Sci. USA 105, 14981-14986 (2008).
14. Diallo, J. S. et al. A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol. Ther. 18, 1123-1129 (2010).
15. Terkeltaub, R. A. Colchicine update: 2008. Semin. Arthritis Rheum. 38, 411-419 (2009).
16. Brun, J. et al. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol. Ther. 18, 1440-1449 (2010).
17. Martello, L. A. et al. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549cell line with an alpha-tubulin mutation. Cancer Res. 63, 1207-1213 (2003).
18. Ruiz Gomez, M. J., Gil, L., Souviron, A. & Martinez Morillo, M. Multidrug resistance increment in a human colon carcinoma cell line by colchicine. J. Physiol. Biochem. 56, 33-38 (2000).
19. Connolly, D. C. et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 63, 1389-1397 (2003).
20. Garson, K., Gamwell, L. F., Pitre, E. M. & Vanderhyden, B. C. Technical challenges and limitations of current mouse models of ovarian cancer. J. Ovarian Res. 5, 39 (2012).
21. Eden, E., Navon, R., Steinfeld, I., Lipson, D. & Yakhini, Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 10, 48 (2009).
22. Eden, E., Lipson, D., Yogev, S. & Yakhini, Z. Discovering motifs in ranked lists of DNA sequences. PLoS Comput. Biol. 3, e39 (2007).
23. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
24. Huang da, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1-13 (2009).
25. Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375-386 (2005).
26. Li, Z., Davis, G. S., Mohr, C., Nain, M. & Gemsa, D. Suppression of LPSinduced tumor necrosis factor-alpha gene expression by microtubule disrupting agents. Immunobiology 195, 640-654 (1996).
27. Lacy, P. E., Howell, S. L., Young, D. A. & Fink, C. J. New hypothesis of insulin secretion. Nature 219, 1177-1179 (1968).
28. Le Marchand, Y. et al. A role for the microtubular system in the release of very low density lipoproteins by perfused mouse livers. J. Biol. Chem. 248, 6862-6870 (1973).
29. Zurier, R. B., Hoffstein, S. & Weissmann, G. Mechanisms of lysosomal enzyme release from human leukocytes. I. Effect of cyclic nucleotides and colchicine. J. Cell Biol. 58, 27-41 (1973).
30. Williams, J. A. & Wolff, J. Colchicine-binding protein and the secretion of thyroid hormone. J. Cell Biol. 54, 157-165 (1972).
31. Colina, R. et al. Translational control of the innate immune response through IRF-7. Nature 452, 323-328 (2008).
32. Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253-265 (2004).
33. Conrad, D. P. et al. Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia. Clin. Cancer Res. 19, 3832-3843 (2013).
34. Das, S. C., Nayak, D., Zhou, Y. & Pattnaik, A. K. Visualization of intracellular transport of vesicular stomatitis virus nucleocapsids in living cells. J. Virol. 80, 6368-6377 (2006).
35. Smith, G. L., Vanderplasschen, A. & Law, M. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83, 2915-2931 (2002).
36. Herrero-Martinez, E., Roberts, K. L., Hollinshead, M. & Smith, G. L. Vaccinia virus intracellular enveloped virions move to the cell periphery on microtubules in the absence of the A36R protein. J. Gen. Virol. 86, 2961-2968 (2005).
37. Passer, B. J. et al. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models. Cancer Gene. Ther. 20, 17-24 (2013).
38. Pestka, S. The interferons: 50 years after their discovery, there is much more to learn. J. Biol. Chem. 282, 20047-20051 (2007).
39. Zhou, B. & Rabinovitch, M. Microtubule involvement in translational regulation of fibronectin expression by light chain 3 of microtubule-associated protein 1 in vascular smooth muscle cells. Circ. Res. 83, 481-489 (1998).
40. Havercroft, J. C., Quinlan, R. A. & Gull, K. Binding of parbendazole to tubulin and its influence on microtubules in tissue-culture cells as revealed by immunofluorescence microscopy. J. Cell Sci. 49, 195-204 (1981).
41. Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. New Engl. J. Med. 367, 1783-1791 (2012).
42. Lemay, C. G. et al. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol. Ther. 20, 1791-1799 (2012).
43. Diallo, J. S., Vaha-Koskela, M., Le Boeuf, F. & Bell, J. Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains. Methods Mol. Biol. 797, 127-140 (2012).
44. Le Boeuf, F. et al. Synergistic interaction between oncolytic viruses augments tumor killing. Mol. Ther. 18, 888-895 (2010).
45. Emig, D. et al. AltAnalyze and DomainGraph: analyzing and visualizing exon expression data. Nucleic Acids Res. 38, W755-W762 (2010).
46. Vultur, A. et al. Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells. Oncogene 23, 2600-2616 (2004).
47. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).